Trial reportFrontiers in medicine2026
Effect of tegileridine pretreatment on fentanyl-induced cough during general anesthesia induction: a randomized controlled trial.
Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fentanyl-induced cough (FIC) is a common adverse reaction during anesthetic induction. Although usually transient, FIC may increase intracranial, intraocular, and intra-abdominal pressures and cause serious complications. Tegileridine (SHR8554), a G-protein-biased μ-opioid receptor agonist, may modulate opioid-induced cough, although the underlying mechanism remains unproven. This study evaluated whether tegileridine pretreatment reduces FIC. Methods: In this prospective, randomized, double-blind, placebo-controlled trial, 232 adults scheduled for elective surgery under general anesthesia were screened, and 216 were randomized to receive tegileridine 0.5 mg diluted to 5 mL (Group T) or 5 mL normal saline (Group C). The study drug was injected intravenously over 10 s immediately before rapid fentanyl injection (4 μg·kg Results: FIC occurred in 31 of 108 patients in Group C and 12 of 108 patients in Group T (28.7% vs. 11.1%; χ Conclusion: Tegileridine 0.5 mg pretreatment reduced the incidence and severity of FIC without evidence of immediate hemodynamic instability. Further active-comparator, dose-finding, and broader safety studies are required before routine clinical adoption. Clinical trial registration: https://www.chictr.org.cn/searchproj.html, identifier: ChiCTR2500115512.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.